Rituximab, for example, has already been used successfully in the context of N-methyl-D-aspartate receptor (NMDAR) or contactin-associated protein-like 2 (CASPR2) encephalitis, which supports the future application of more recent humanized anti-CD20 antibodies, such as ofatumumab or ocrelizumab, in post-ICI neurotoxicity. Here, CNTNAP2 is linked to encephalitis.